Intracranial Stents

Intracranial Stents

Global Intracranial Stents Market to Reach US$883.3 Million by 2030

The global market for Intracranial Stents estimated at US$376.3 Million in the year 2023, is expected to reach US$883.3 Million by 2030, growing at a CAGR of 13.0% over the analysis period 2023-2030. Self-Expanding Stents, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$594.0 Million by the end of the analysis period. Growth in the Balloon Expanding Stents segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$101.4 Million While China is Forecast to Grow at 17.9% CAGR

The Intracranial Stents market in the U.S. is estimated at US$101.4 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$207.9 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.3% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Intracranial Stents- Key Trends and Drivers Summarized

Intracranial stenting has become an essential treatment for intracranial atherosclerotic stenosis (ICAS), a major cause of stroke, particularly in Asian populations. Despite various treatment strategies including surgery and medication, endovascular treatments like stenting have gained prominence. However, comparative studies such as the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial suggest that while stenting is effective in certain scenarios, it does not universally outperform medical management. The trials indicate that stenting may be particularly beneficial for patients with specific types of strokes and those who have high recurrent stroke rates due to conditions like impaired collateral flow. The technology faces challenges, including regulatory restrictions on patient selection and the management of periprocedural risks such as unstable plaque and hyperperfusion, which are significant in determining the timing and success of stenting procedures.

The potential of intracranial stents is being further explored through innovations such as drug-eluting stents (DES), which have been successful in coronary artery disease treatments by reducing in-stent stenosis. The application of DES in treating intracranial atherosclerosis holds promise, necessitating further studies to fully evaluate their benefits and risks in larger patient groups and over longer periods. Moreover, ongoing advancements in stenting technology and techniques continue to enhance the safety and effectiveness of these interventions in managing ICAS. The exploration of new stenting technologies and procedural advancements are crucial to improving outcomes and expanding the applicability of intracranial stents in clinical settings.

The growth in the intracranial stents market is driven by several key factors. The increasing prevalence of conditions like intracranial aneurysms and strokes catalyzes the demand for effective stenting solutions. Technological advancements in stent design and materials, coupled with a growing aging population at risk for cerebrovascular diseases, further stimulate this demand. Supportive government policies and rising healthcare expenditures globally also contribute to the adoption of advanced medical treatments like intracranial stenting. Additionally, the rising popularity of minimally invasive procedures, improved diagnostic techniques, and expansions in healthcare infrastructure support the broader use of intracranial stents. Partnerships between hospitals, academic institutions, and device manufacturers, along with favorable insurance and reimbursement policies, are crucial in driving innovation and facilitating the accessibility of these critical treatments. Together, these factors underscore the dynamic growth and vital role of intracranial stents in contemporary medical practice, addressing complex neurological conditions effectively.

Select Competitors (Total 14 Featured) -

• Boston Scientific Corporation
• Cook Medical, Inc.
• Johnson & Johnson
• Medtronic PLC
• Penumbra, Inc.
• Stryker Corporation
• Terumo Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.